Leap Therapeutics (LPTX) Stock Forecast & Price Target

Leap Therapeutics Inc. has demonstrated promising clinical efficacy with its lead drug candidate, sirexatamab, which showcases an overall response rate (ORR) of 33% and a disease control rate (DCR) of 93% in patients as of the most recent data cut-off. The company’s management indicates that the positive objective response data in colorectal cancer (CRC) is compelling enough to engage with the FDA regarding a potential regulatory pathway, particularly highlighting an ORR of 53% in bevacizumab-naïve patients. Additionally, a correlation has been observed between treatment efficacy and increased serum levels of DKK1, further supporting the potential of their targeted therapy approach in enhancing patient outcomes.

Leap Therapeutics Inc has reported a stable overall response rate (ORR) of 33% for its lead clinical candidate, sirexatamab, with a disease control rate (DCR) also holding steady at 93%, which may indicate a lack of substantial improvement in efficacy over time. The company's decision not to advance sirexatamab into Phase 3 evaluation for specific indications reflects a troubling trend of reduced efficacy as indicated by lower median progression-free survival (mPFS) compared to controls, contributing to concerns over the viability of its pipeline. Additionally, the absence of meaningful catalysts for upcoming developments has led to a downgrading in the stock's outlook, highlighting significant uncertainties surrounding the company’s future performance.